Literature DB >> 16275832

Progression of motor impairment and disability in Parkinson disease: a population-based study.

Guido Alves1, Tore Wentzel-Larsen, Dag Aarsland, Jan Petter Larsen.   

Abstract

OBJECTIVE: To investigate risk factors and the rate of progression of motor symptoms and disability in a population-based cohort of patients with Parkinson disease (PD).
METHODS: In all, 232 patients with PD, derived from a community-based prevalence study, were followed prospectively over an 8-year period. Follow-up examinations were done 4 and 8 years after baseline, and 144 patients participated in at least one follow-up examination. Information on motor function and disability was obtained using the Unified Parkinson Disease Rating Scale (UPDRS), the Hoehn and Yahr staging, and the Schwab and England score. Population-averaged logistic regression models were used to describe annual disease progression and to analyze the influence of potential risk factors on functional decline.
RESULTS: We found a similar mean annual decline in the UPDRS motor score and the Hoehn and Yahr staging of 3.1% and 3.2%, respectively. Also the UPDRS Activity of Daily Living (ADL) score and the Schwab and England scale changed similarly, with 3.5% and 3.6% per year, respectively. Age, age at onset, disease duration, and excessive daytime somnolence at baseline were strong and independent predictors of greater impairment in motor function and disability. Cognitive impairment at baseline predicted higher disability and higher Hoehn and Yahr scores. Time by age-at-onset interactions were found for the UPDRS motor score and the Hoehn and Yahr staging.
CONCLUSIONS: Motor function and disability worsened significantly with time, and to a similar extent. Age, age at onset and disease duration, as well as symptoms thought to be due to involvement of non-dopaminergic brain structures, are predictors of more impaired motor function and disability. However, age at disease onset was the main predictor of motor decline in our cohort, indicating a slower and more restricted pathologic disease process in patients with young-onset PD.

Entities:  

Mesh:

Year:  2005        PMID: 16275832     DOI: 10.1212/01.wnl.0000183359.50822.f2

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  67 in total

Review 1.  Epidemiology of Parkinson's disease.

Authors:  Guido Alves; Elin Bjelland Forsaa; Kenn Freddy Pedersen; Michaela Dreetz Gjerstad; Jan Petter Larsen
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

2.  Health state values during the first year of drug treatment in early-stage Parkinson's disease: a prospective, population-based, cohort study.

Authors:  Corinna Vossius; Odd Bjarte Nilsen; Jan Petter Larsen
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

3.  Clinical characteristics related to worsening of motor function assessed by the Unified Parkinson's Disease Rating Scale in the elderly population.

Authors:  Inga Liepelt-Scarfone; Stefanie Lerche; Stefanie Behnke; Jana Godau; Alexandra Gaenslen; Christoph Pausch; Klaus Fassbender; Kathrin Brockmann; Karin Srulijes; Heiko Huber; Isabel Wurster; Daniela Berg
Journal:  J Neurol       Date:  2014-12-02       Impact factor: 4.849

Review 4.  Integrating Patient Concerns into Parkinson's Disease Management.

Authors:  Shen-Yang Lim; Ai Huey Tan; Susan H Fox; Andrew H Evans; Soon Chai Low
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

5.  Dynamics of change in self-reported disability among persons with Parkinson's disease after 2 years of follow-up.

Authors:  Tatjana Gazibara; Darija Kisic-Tepavcevic; Marina Svetel; Aleksandra Tomic; Iva Stankovic; Vladimir Kostic; Tatjana Pekmezovic
Journal:  Neurol Sci       Date:  2017-05-13       Impact factor: 3.307

6.  Tandem gait performance in essential tremor: clinical correlates and association with midline tremors.

Authors:  Elan D Louis; Eileen Rios; Ashwini K Rao
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

7.  Exercise for people in early- or mid-stage Parkinson disease: a 16-month randomized controlled trial.

Authors:  Margaret Schenkman; Deborah A Hall; Anna E Barón; Robert S Schwartz; Pamela Mettler; Wendy M Kohrt
Journal:  Phys Ther       Date:  2012-07-19

8.  Changes in network activity with the progression of Parkinson's disease.

Authors:  Chaorui Huang; Chengke Tang; Andrew Feigin; Martin Lesser; Yilong Ma; Michael Pourfar; Vijay Dhawan; David Eidelberg
Journal:  Brain       Date:  2007-04-30       Impact factor: 13.501

Review 9.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

10.  Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.

Authors:  Nir Giladi; Anthony P Nicholas; Mahnaz Asgharnejad; Elisabeth Dohin; Franz Woltering; Lars Bauer; Werner Poewe
Journal:  J Parkinsons Dis       Date:  2016-10-19       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.